NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.



Don't have an account? Subscribe

ADVERTISEMENT

ADVERTISEMENT

Positive results from phase 3 lung and breast cancer trials

By Mindo - 19th Nov 2023

trials

Positive results from the TROPION-Breast01 phase 3 trial showed that a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd), demonstrated a statistically significant and clinically meaningful improvement in PFS compared to investigator’s choice of single-agent chemotherapy in patients with inoperable or metastatic hormone receptor (HR) positive, HER2 low or negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer previously treated with endocrine-based therapy and at least one systemic therapy.

In the dual primary endpoint analysis, Dato-DXd reduced the risk of disease progression or death by 37 per cent compared to investigator’s choice of chemotherapy [HR=0.63; 95% CI: 0.52-0.76; p<0.0001] in patients with HR positive, HER2 low or negative metastatic breast cancer as assessed by blinded independent central review (BICR). Median PFS was 6.9 months in patients treated with Dato-DXd compared to 4.9 months in those treated with chemotherapy. A consistent benefit in PFS was observed across subgroups. Results also showed a confirmed objective response rate (ORR) of 36.4 per cent in patients treated with Dato-DXd compared to an ORR of 22.9 per cent in patients treated with chemotherapy. TROPION-Breast01 enrolled more than 700 patients at sites in Asia, Europe, North America, South America, and Africa.

Meanwhile, positive results from the pivotal TROPION-Lung01 phase 3 trial showed that Dato-DXd demonstrated a statistically significant improvement for the primary endpoint of PFS compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy.

Dato-DXd reduced the risk of disease progression or death by 25 per cent compared to docetaxel [HR=0.75; 95% CI: 0.62-0.91; p=0.004] as assessed by BICR. Median PFS was 4.4 months in patients treated with Dato-DXd compared to 3.7 months with docetaxel. Results also showed a confirmed ORR of 26.4 per cent in patients treated with Dato-DXd compared to an ORR of 12.8 per cent in patients treated with docetaxel. Median duration of response (DoR) was 7.1 months [95% CI: 5.6-10.9] in the Dato-DXd arm compared to 5.6 months [95% CI: 5.4-8.1] in the docetaxel arm.

These data were presented as two positive late-breaking presentations (LBA12) from the Dato-DXd clinical development programme, during the Presidential Symposium 3 at the ESMO 2023 Congress.

Leave a Reply

ADVERTISEMENT

Latest

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

Latest Issue
The Medical Independent 2nd April 2024

You need to be logged in to access this content. Please login or sign up using the links below.

ADVERTISEMENT

Most Read

ADVERTISEMENT

ADVERTISEMENT